logo
EXCLUSIVE: DeFi Development Buys $19 Million In Solana

EXCLUSIVE: DeFi Development Buys $19 Million In Solana

Yahoo21-07-2025
DeFi Development (NASDAQ:DFDV) announced on Monday that it has 999,999 Solana (CRYPTO: SOL/USD) and SOL equivalents on its balance sheet.
The company purchased 141,383 SOL between July 14 and July 20, at an average purchase price of $133.53, representing approximately $19 million. The purchased SOL includes both spot purchases and discounted locked SOL.
The company's SOL position includes rewards from staking and on-chain activities.As of July 20, 2025, DeFi Development held 999,999 SOL and SOL equivalents, an increase of 142,250 from its previous balance of 857,749. It held SOL and SOL equivalents worth $181 million.
The company earned close to 867 SOL via staking, validator revenue, and other on-chain activity between July 14 and July 20
DeFi Development held 19,445,837 shares outstanding as of July 18, 2025. SOL per Share ("SPS") of 0.0514, representing an approximate 13% increase week-over-week. SPS was worth $9.30.
The newly acquired SOL will be held long-term and staked to various validators, including DeFi Development's own Solana validators, to generate native yield.
Month-to-date, DeFi Development raised approximately $19.2 million in net proceeds through its Equity Line of Credit facility, issuing 740,000 shares of common stock. Roughly $5 million of the proceeds remains available primarily for future SOL purchases.
To date, DeFi Development has drawn 0.4% of the total available capacity under its credit facility. Approximately $4.98 billion remains available under the facility.
Last week, DeFi Development outlined a medium-term objective of reaching 1.0 SPS by December 2028 and near-term guidance of 0.1650 SPS by June 2026, representing approximately 261% growth from Monday's level of 0.0457.
Price Action: DFDV stock traded higher by 11.2% to $27.14 premarket at the last check Monday.
Photo by Lee Wa Da via Shutterstock
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article EXCLUSIVE: DeFi Development Buys $19 Million In Solana originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Metagenomi (MGX) Presents Latest in Gene Editing Technologies
Metagenomi (MGX) Presents Latest in Gene Editing Technologies

Yahoo

time8 minutes ago

  • Yahoo

Metagenomi (MGX) Presents Latest in Gene Editing Technologies

Metagenomi, Inc. (NASDAQ:MGX) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 14, Metagenomi, Inc. (NASDAQ:MGX) announced that it is presenting three abstracts at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, held from May 13 to 17, 2025, in New Orleans, Louisiana. These presentations highlighted Metagenomi, Inc.'s (NASDAQ:MGX) advancements in compact nucleases for extrahepatic gene editing and CAST (CRISPR-associated transposases) for site-specific integration of large therapeutic genes. A lab scientist peering into a microscope focused on gene editing technology. The company's special metagenomics discovery platform can systematically identify and optimize novel gene editing systems through natural microbial evolution and AI-guided protein optimization. At the meeting, Metagenomi, Inc. (NASDAQ:MGX) shared early proof-of-concept data across different types of gene-editing technologies. This included compact Type II and Type V nucleases for efficient in vivo editing and a programmable Type V-K CAST system capable of targeted integration of large DNA cargoes. The small nucleases can potentially improve delivery to hard-to-reach tissues, while CAST offers promising new tools for targeted and precise large gene integration, addressing one of the greatest challenges in gene editing. Metagenomi, Inc.'s (NASDAQ:MGX) work shows promise in specifically integrating correct copies of complete genes, which could enable treatment for diseases caused by a loss-of-function mutation. Metagenomi, Inc. (NASDAQ:MGX) is a precision gene editing company focused on developing curative therapeutics using its proprietary, metagenomics-derived genome editing toolbox. While we acknowledge the potential of MGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Apple (AAPL) Faces Margin Pressures Ahead of Earnings — BofA Still Says Buy
Apple (AAPL) Faces Margin Pressures Ahead of Earnings — BofA Still Says Buy

Yahoo

time8 minutes ago

  • Yahoo

Apple (AAPL) Faces Margin Pressures Ahead of Earnings — BofA Still Says Buy

Apple Inc. (NASDAQ:AAPL) is one of the . On July 28, Bank of America maintained a 'Buy' rating on the stock with a price target of $235. The firm believes that Apple faces a tough setup as it heads into its third fiscal quarter results due on July 31st. Investors continue to watch closely for margin pressures from tariffs and ongoing regulatory concerns. 'We see client sentiment as fairly negative given uncertain impact from tariffs, U.S. DOJ investigation (Google (NASDAQ:GOOGL) TAC payments), App Store headwinds, and slow progress in AI.' -BofA analysts wrote in a note. The firm believes that gross margins (GM) are going to be the highlight of the earnings report, with the June quarter guide of 46% at the mid-point, which includes the 'impact of $900mn of tariff-related costs.' Copyright: dennizn / 123RF Stock Photo It models the September quarter period as the 'trough,' anticipating gross margins to improve on the back of a 'better mix of higher ASP products, including the slim iPhone ('Air'), which we expect Apple to launch this fall.' While margin concerns exist, the firm anticipates in-line results for the current quarter and also potentially a slight revenue beat. Upcoming product cycles may also prove to be good for the company, as 'iPhone form factor changes have helped drive higher replacement rates in the past.' Apple is a technology company known for its consumer electronics, software, and services. While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio

ACI Worldwide (ACIW) Slid on Investors' Concerns Over Unchanged Guidance
ACI Worldwide (ACIW) Slid on Investors' Concerns Over Unchanged Guidance

Yahoo

time8 minutes ago

  • Yahoo

ACI Worldwide (ACIW) Slid on Investors' Concerns Over Unchanged Guidance

The London Company, an investment management company, released 'The London Company Small Cap Strategy' second quarter 2025 investor letter. A copy of the letter can be downloaded here. Following a significant downturn in the first quarter, U.S. equities saw a double-digit rise in the second quarter. The small-cap portfolio appreciated 2.7% (2.4% net) in the second quarter, lagging behind the Russell 2000 Index's 8.5% gain. Sector allocation contributed to the relative performance, while stock selection was a headwind. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second quarter 2025 investor letter, The London Company Small Cap Strategy highlighted stocks such as ACI Worldwide, Inc. (NASDAQ:ACIW). ACI Worldwide, Inc. (NASDAQ:ACIW) is a software company that develops, installs, and supports a wide range of software products and solutions to facilitate digital payments. The one-month return of ACI Worldwide, Inc. (NASDAQ:ACIW) was -3.09%, and its shares gained 4.07% of their value over the last 52 weeks. On July 28, 2025, ACI Worldwide, Inc. (NASDAQ:ACIW) stock closed at $44.52 per share, with a market capitalization of $4.67 billion. The London Company Small Cap Strategy stated the following regarding ACI Worldwide, Inc. (NASDAQ:ACIW) in its second quarter 2025 investor letter: "ACI Worldwide, Inc. (NASDAQ:ACIW) – ACIW was a bottom performer due to investor disappointment over unchanged guidance, despite robust results. The company's stable business, underpinned by a high proportion of recurring revenues and nearly a year of revenue visibility from its contracted backlog, supports our positive outlook. Sustained organic growth and insider buying by the CEO during the stock pullback reinforce confidence in ACIW's long-term potential." A businesswoman using a digital tablet, making a payment using the company's payment processing technology. ACI Worldwide, Inc. (NASDAQ:ACIW) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held ACI Worldwide, Inc. (NASDAQ:ACIW) at the end of the first quarter, which was 35 in the previous quarter. While we acknowledge the potential of ACI Worldwide, Inc. (NASDAQ:ACIW) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered ACI Worldwide, Inc. (NASDAQ:ACIW) and shared the list of Aristotle Capital Small Cap Equity Strategy's views on the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store